65岁及以上女性Pap与高危HPV检测及手术病理随访
本研究回顾性分析了某妇女医院2023年1月至2024年12月65岁及以上女性的Pap检测和HPV检测结果,并记录6个月内手术病理随访。总体HPV阳性率为24.2%,Pap异常率为61.1%,在402例有组织学随访的病例中,CIN2及以上病变占23.3%,且部分鳞癌和CIN2/3为HPV阴性。结论提示该人群Pap异常率高而HPV阳性率低,Pap与HPV联合筛查可能使老年女性获益。
要点
- 65岁及以上女性Pap异常率高达61.1%,HPV阳性率为24.2%。
- 有组织学随访的402例中CIN2及以上病变占23.3%,含子宫内膜癌40例。
- 11例鳞癌中3例(27.3%)和40例CIN2/3中12例(30%)为HPV阴性。
核心结论
- 65岁及以上女性Pap异常率高(61.1%)而HPV阳性率相对低(24.2%)。
- HPV阴性后仍出现CIN2及以上病变和子宫内膜病变的比例为33.8%。
研究设计与样本
- 回顾性研究,纳入2023年1月至2024年12月某妇女医院65岁及以上女性的Pap检测。
- Pap采用ThinPrep液基细胞学,高危HPV采用Aptima检测,记录6个月内手术病理随访。
主要发现
- 共1536例65岁及以上女性接受Pap检测,总体HPV阳性率为24.2%。
- Pap异常(ASC-US及以上)939/1536例(61.1%),402例有组织学随访。
- 94例(23.3%)为CIN2及以上病变,包括11例鳞癌、3例宫颈腺癌、40例CIN2/3和40例子宫内膜癌。
- 11例鳞癌中3例(27.3%)HPV阴性,40例CIN2/3中12例(30%)HPV阴性。
- 不典型腺细胞检出率为3.0%,与较多子宫内膜癌诊断相关。
临床怎么用
- 对65岁及以上女性,Pap与HPV联合筛查可能有益,尤其需关注HPV阴性但Pap异常者。
局限性
- 原文未明确报告局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current professional guidelines recommend discontinuing Papanicolaou (Pap) test screening in women aged 65 years and older who have had adequate prior negative testing. However, limited data exist on Pap test performance and histologic outcomes in this population. METHODS: Searches were performed for all Pap tests from women aged 65 years and older accessioned at a women's hospital between January 2023 and December 2024. Pap tests were performed using the liquid-based cytology ThinPrep test, and high-risk HPV testing was performed using Aptima high-risk human papillomavirus (HPV) assays. Surgical pathology follow-up within 6 months was recorded. A Pearson χ2 test was performed to compare HPV positivity among patients who had abnormal Pap tests. RESULTS: In total, 1536 women aged 65 years and older underwent Pap testing during the study period. The overall HPV-positivity rate was 24.2%. Abnormal Pap results (atypical squamous cells of undetermined significance or worse) comprised 939 of 1536 cases (61.1%). Histologic follow-up was available for 402 cases. Lesions categorized as cervical intraepithelial neoplasia grade 2 (CIN2) or more severe disease were identified in 94 cases (23.3%), including 11 squamous cell carcinomas, three endocervical carcinomas, 40 CIN2/3 lesions, and 40 endometrial carcinomas. Notably, three of 11 squamous cell carcinomas (27.3%) and 12 of 40 CIN2/3 lesions (30%) were HPV-negative. CONCLUSIONS: The abnormal Pap rate in women aged 65 years and older was high (61.1%), whereas HPV positivity remained low. CIN2 or more severe disease and endometrial lesions after negative HPV testing occurred at a substantial rate (33.8%). The rate for detecting atypical glandular cells was also elevated (3.0%), correlating with a significant number of endometrial carcinoma diagnoses. These findings underscore the need for additional research and suggest that continued screening with Pap and HPV cotesting may benefit older women.
引用
- Ramseyer TG, Batson B, Wu D, et al. Pap testing and high-risk HPV testing for women aged 65 years and older with surgical pathology follow-up. Cancer Cytopathol. 2026. PMID: 42080588. doi:10.1002/cncy.70111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。